ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ:NVCR) announced today that it will participate in Noble
Capital Markets’ 13th Annual Investor Conference on Jan. 31, 2017, in
Boca Raton, Florida. Ashley Cordova, Novocure’s Vice President of
Finance and Investor Relations, will speak on behalf of the company and
address questions from analysts.
Ms. Cordova’s presentation will begin at 1 p.m. EST. The audio replay
and presentation materials will be available via Novocure.com for
at least 14 days following the presentation.
About Novocure
Novocure is a commercial-stage oncology company developing a proprietary
therapy called Tumor Treating Fields, or TTFields, for the treatment of
solid tumor cancers. Novocure’s commercialized product, Optune, is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed phase 2 pilot trials investigating TTFields in
non-small cell lung cancer, pancreatic cancer, ovarian cancer and
mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the
company has offices in Germany, Switzerland and Japan, and a research
center in Haifa, Israel. For additional information about the company,
please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and
Exchange Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.
Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170124005722/en/
Source: Novocure